OakChart

Profusa Inc

PFSAHealthcare·Medical Devices·USA·Nano·NASD·Nov 11 • 8:41 AM ET

0.5714+0.0224 (4.08%)
2026-11-11 14:54 CET
Market cap
0.33 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-42.97 USD m
Free cash flow, TTM
-21.04 USD m
EPS diluted, TTM
-6,297.20
P/E
-
Compare

Price

PFSA against its 20, 50 and 200-day averages
2050200
0.00500.001,000.001,500.0039.6M79.3MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26PFSAclose 0.5720-day 0.7550-day 1.51200-day 63.280.57

100.0% under 2,175.00 on 30 Oct 2025. Last 15 sessions, 164.7% high to low

Profile

PFSA
52-week range, 0% of the way up
0.511,594

Profusa, Inc. engages in biofeedback for chronic disease management and healthy living services. The company is founded by Natalie Wisniewski and Bill McMillan and is headquartered in Berkeley, CA.

IPOJan 24, 2022
Beta5.05
ATR, 14d0.21
Rel volume0.02
Short float18.95%
Insider own14.34%
Inst own0.39%

Snapshot

6 groups

Valuation

Index-
Market Cap0.34M
Enterprise Value13.62M
Income-42.97M
Sales0.00M
Book/sh-205.03
Cash/sh1.20
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees-
IPOJan 24, 2022

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B-
P/C0.48
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio0.03
Current Ratio0.03
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-6297.20
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y- -
Sales past 3/5Y- -
EPS Y/Y TTM72.63%
Sales Y/Y TTM-
EPS Q/Q98.72%
Sales Q/Q-
Earnings-
EPS/Sales Surpr.- -

Ownership

Insider Own14.34%
Insider Trans-25.80%
Inst Own0.39%
Inst Trans-0.53%
ROA-2860.46%
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-23.56%
SMA50-62.26%
SMA200-99.10%
Trades-

Technical

Shs Outstand0.61M
Shs Float0.52M
Short Float18.95%
Short Ratio0.03
Short Interest0.10M
52W High1593.75 -99.96%
52W Low0.51 12.04%
Volatility9.95% 15.18%
ATR (14)0.21
RSI (14)34.84
Beta5.05
Rel Volume0.02
Avg Volume3.48M
Volume3,522

Performance

Perf Week-7.41%
Perf Month-55.36%
Perf Quarter-84.97%
Perf Half Y-98.67%
Perf YTD-99.93%
Perf Year-99.96%
Perf 3Y-100.00%
Perf 5Y-
Perf 10Y-
Recom-
Target Price-
Prev Close0.55
Price0.57
Change %4.08%

Peers

Mkt cap
TickerCompanyMkt cap
SENSSenseonics Holdings Inc575.20M
DXCMDexcom Inc29.73B
INBSIntelligent Bio Solutions Inc7.46M
MODDModular Medical Inc15.86M
HSCSHeartSciences Inc12.00M
BBNXBeta Bionics Inc937.28M
VNRXVolitionRX Ltd5.51M
BEATHeartBeam Inc22.87M
DRIODarioHealth Corp23.42M

Insider trading

14 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
HRT FINANCIAL LP10% OwnerAug 17 '26Sale5.9418,395109,2660Aug 19 03:19 PM
HRT FINANCIAL LP10% OwnerAug 14 '26Sale0.903,1632,85371,035Aug 18 04:02 PM
HRT FINANCIAL LP10% OwnerAug 12 '26Buy0.965,5855,384116,609Aug 14 12:29 PM
HRT FINANCIAL LP10% OwnerAug 13 '26Sale0.8942,41137,66174,198Aug 14 12:29 PM
HRT FINANCIAL LP10% OwnerAug 10 '26Buy0.944,0163,791113,304Aug 12 03:13 PM
HRT FINANCIAL LP10% OwnerAug 11 '26Sale0.972,2802,212111,024Aug 12 03:13 PM
HRT FINANCIAL LP10% OwnerAug 06 '26Buy0.94926873110,212Aug 10 03:39 PM
HRT FINANCIAL LP10% OwnerAug 07 '26Sale0.95924874109,288Aug 10 03:39 PM
HRT FINANCIAL LP10% OwnerAug 05 '26Sale0.94383361109,286Aug 10 03:39 PM
HRT FINANCIAL LP10% OwnerAug 03 '26Buy0.9614,55613,945108,301Aug 05 01:53 PM
HRT FINANCIAL LP10% OwnerAug 04 '26Buy0.951,3681,305109,669Aug 05 01:53 PM
HRT FINANCIAL LP10% OwnerJul 31 '26Buy1.058,8119,25293,745Aug 03 04:04 PM
HRT FINANCIAL LP10% OwnerJul 30 '26Buy1.011,0631,07484,934Aug 03 04:04 PM
HRT FINANCIAL LP10% OwnerJul 29 '26Buy1.011,3101,32383,871Jul 30 03:00 PM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.61B

News

latest 14 of 116
  • Profusa Receives ISO 13485:2016 Certificate from GMED (GlobeNewswire) -16.41%
  • Profusa ISO 13485 Certification Decision Advances Lumee Oxygen Platform Toward CE Mark (InvestorsHub) +47.80%
  • Profusa Announces Significant Progress Towards Lumee Oxygen Platform CE Mark with ISO 13485 Certification Expected in Early October (GlobeNewswire)
  • Profusa, Inc. Receives Nasdaq Compliance Determination (GlobeNewswire) -29.34%
  • Profusa, Inc. Announces Compliance with Nasdaq Publicly Held Shares Requirement (GlobeNewswire)
  • Loading…
  • Profusa Advances G3 Vision Labs Acquisition Conditions as Q2 Net Loss Widens (InvestorsHub) -44.22%
  • Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company (GlobeNewswire)
  • Profusa Announces 1-for-4 Reverse Stock Split (GlobeNewswire)
  • Profusa vies for potential G3 Vision Labs acquisition (Medical Device Network) -9.19%
  • Profusa Announces Signing of Option Agreement for the Acquisition of a Commercial Stage Diagnostics Company, G3 Vision Labs (GlobeNewswire)
  • Profusa Signs Term Sheet for Diagnostics Acquisition and Announces Leadership Changes (InvestorsHub) -28.65%
  • Profusa Announces Key Management Changes and Signing of Non-Binding Term Sheet for the Acquisition of a Commercial Stage Diagnostics Company (GlobeNewswire)
  • This Biotech Stock Crashed 28% Today After Announcing Second Reverse Share Split This Year (Stocktwits) -28.08%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
No quarterly earnings.

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
No estimate revisions.

Estimate history

EPS, annual93.2252224.275866.25-35713.425-10700.775-6297.197
Period20212022202320242025TTM
EPS, quarterly-573.975115.275-9672.675-1617.225-11836.65-5245.35-695.325-204.726-151.796
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000.100
Period20212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.0030.0030.00100.0120.132
Period20212022202320242025MRQ
Shares, quarterly0.0010.0010.0010.0010.0010.0060.0120.0240.132
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Total Revenue0.000.000.100.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.00
Gross Profit-0.000.000.000.000.000.00
Selling, General and Administrative Excl. Other32.4113.224.601.511.270.05
Research and Development3.942.801.61---
Other Operating Expense0.000.000.000.000.000.00
Operating Income-32.41-13.22-4.50-1.51-1.27-0.05
Interest Expense5.285.094.42-0.000.00
Unusual Expense5.1317.520.31-0.88-6.36-0.34
Net Income Before Taxes-42.97-35.82-9.231.627.670.30
Income Taxes0.000.000.000.460.500.00
Consolidated Net Income-42.97-35.82-9.231.167.170.30
Net Income From Continuing Operations-42.97-35.82-9.231.167.170.30
Net Income-42.97-35.82-9.231.167.170.30
EPS (Recurring)-682.74-7,037.15-34,871.05407.59843.1319.59
EPS (Basic, Before Extraordinaries)-6,297.20-10,700.77-35,713.43866.252,224.2893.22
EPS (Diluted)-6,297.20-10,700.77-35,713.43866.252,224.2893.22
EBITDA-32.41-13.22-4.50-1.51-1.27-0.05
Non-Operating Income (Expense)-0.150.020.012.252.580.01
Other After Tax Adjustments0.000.000.000.000.000.00
Stock Option Compensation Expense1.180.890.02---
Price To Earnings Ratio---94.0335.0535.05
Price To Sales Ratio--214.87---
Gross Margin--0.00---
Operating Margin---4,500.00---
Net Margin---9,230.00---
Shares Outstanding0.130.010.000.000.000.00
Market Capitalization0.330.3368.8768.83244.83244.83

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.00
Gross Profit-0.000.000.000.000.000.000.000.00
Selling, General and Administrative Excl. Other2.544.014.1521.710.970.580.310.32
Research and Development0.821.151.250.72----
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.54-4.01-4.15-21.71-0.97-0.58-0.31-0.32
Interest Expense2.430.081.161.61----
Unusual Expense3.83-0.853.27-1.117.240.607.35-0.32
Net Income Before Taxes-8.76-3.46-8.57-22.19-8.19-1.10-7.570.11
Income Taxes0.000.000.000.000.000.020.020.02
Consolidated Net Income-8.76-3.46-8.57-22.19-8.20-1.12-7.590.09
Net Income From Continuing Operations-8.76-3.46-8.57-22.19-8.20-1.12-7.590.09
Net Income-8.76-3.46-8.57-22.19-8.20-1.12-7.590.09
EPS (Recurring)-105.28-240.06-509.83-5,429.64-4,515.64-1,013.83-3,111.45-167.24
EPS (Basic, Before Extraordinaries)-151.80-204.73-695.33-5,245.35-11,836.65-1,617.22-9,672.67115.28
EPS (Diluted)-151.80-204.73-695.33-5,245.35-11,836.65-1,617.22-9,672.67115.28
EBITDA-2.54-4.01-4.15-21.71-0.97-0.58-0.31-0.32
Non-Operating Income (Expense)0.05-0.220.000.010.020.080.090.11
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.190.190.190.62----
Shares Outstanding0.130.020.010.010.000.000.000.00
Market Capitalization0.331.219.6812.3966.2564.7168.8768.81

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY
Cash & Short Term Investments3.220.191.570.190.74
Short Term Receivables0.000.000.000.000.03
Inventories0.000.000.000.000.00
Other Current Assets0.540.070.010.320.33
Total Current Assets3.760.261.580.511.10
Net Property, Plant & Equipment0.010.000.000.000.00
Total Investments and Advances0.000.009.31194.22191.65
Intangible Assets-0.000.000.000.00
Other Assets0.002.810.000.000.31
Total Assets3.773.0710.88194.74193.06
Short Term Debt Incl. Current Port. of LT Debt6.9448.210.940.000.00
Accounts Payable7.344.950.000.000.00
Income Tax Payable-0.000.050.46-
Other Current Liabilities7.973.973.930.470.11
Total Current Liabilities22.2657.134.920.940.11
Long Term Debt7.8865.150.000.000.00
Provision for Risks Charges0.000.000.000.000.00
Deferred Tax Liabilities--0.010.04-
Other Liabilities0.300.000.160.867.22
Total Liabilities30.43122.285.091.837.32
Non-Equity Reserves0.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.00
Common Equity-26.66-119.205.79192.91185.74
Total Shareholders Equity-26.66-119.205.79192.91185.74
Accumulated Minority Interest0.000.000.000.000.00
Total Equity-26.66-119.205.79192.91185.74
Total Liabilities & Stockholders Equity3.773.0710.88194.74193.06
Book Value Per Share-2,163.65-461,236.737,208.4259,862.2257,637.94
Tangible Book Value Per Share-2,163.65-461,236.737,208.4259,862.2257,637.94
Full-Time Employees-2222
Price to Book Ratio-0.00-14.919.641.271.27
Return on Assets-588.87-132.261.133.70-
Return on Equity--1,484.671.173.79-
Return on Invested Capital--20.063.720.16
Quick Ratio0.170.000.320.5510.31
Current Ratio0.170.000.320.5510.31

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Net Income-38.72-35.82-9.231.167.170.30
Other Funds (Non Cash)13.4315.234.76-3.13-8.94-0.35
Funds from Operations-25.29-20.59-4.47-1.97-1.77-0.05
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital4.334.352.41-0.101.19-0.62
Income Taxes Payable---0.05-0.410.46-
Cash from Operating Activities-20.95-16.25-2.07-2.06-0.58-0.66
Capital Expenditures-0.09-0.010.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-8.41-2.000.00184.410.00-191.65
Purchase of Investments-1.90-2.000.00-0.440.00-191.65
Sale Or Maturity of Investments-6.510.000.00184.850.000.00
Other Uses0.000.000.000.000.00-0.03
Other Sources1.070.000.001.190.030.00
Cash from Investing Activities-7.43-2.010.00185.600.03-191.67
Cash Dividends Paid0.000.000.000.000.000.00
Change in Capital Stock19.6410.280.00-184.850.00193.65
Repurchase of Common Pref Stock6.510.000.00-184.850.000.00
Sale of Common Pref Stock13.1310.280.000.000.00193.65
Proceedsfrom Stock Options0.000.000.000.000.00193.65
Issuance or Reduction of Debt, Net9.789.563.081.120.000.00
Change in Long Term Debt12.5011.000.000.000.000.00
Issuance of Long Term Debt12.5011.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.510.00-0.960.000.00-0.57
Other Financing Activities Uses-0.00-0.960.000.00-0.57
Cash from Financing Activities28.9219.842.12-183.720.00193.08
Net Change in Cash0.541.590.05-0.19-0.550.74
Free Cash Flow-21.04-16.26-2.07-2.06-0.58-0.66
Preferred Dividends (Cash Flow)-0.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments0.720.383.223.980.660.02
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.120.290.540.210.030.04
Total Current Assets0.840.663.764.200.690.06
Net Property, Plant & Equipment0.150.160.010.000.000.00
Total Investments and Advances0.000.000.000.001.271.92
Intangible Assets----0.000.00
Other Assets0.050.040.000.060.000.00
Total Assets1.040.863.774.251.961.98
Short Term Debt Incl. Current Port. of LT Debt14.0012.546.946.7110.299.13
Accounts Payable7.868.317.346.980.000.00
Other Current Liabilities6.318.177.979.855.894.12
Total Current Liabilities28.1729.0222.2623.5416.1813.25
Long Term Debt0.000.007.8814.360.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.040.300.316.961.04
Total Liabilities28.1729.0630.4338.2123.1414.30
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-27.13-28.20-26.66-33.96-21.18-12.32
Total Shareholders Equity-27.13-28.20-26.66-33.96-21.18-12.32
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-27.13-28.20-26.66-33.96-21.18-12.32
Total Liabilities & Stockholders Equity1.040.863.774.251.961.98
Book Value Per Share-205.03-1,184.78-2,163.65-6,103.30-29,996.60-17,269.76
Tangible Book Value Per Share-205.03-1,184.78-2,163.65-6,103.30-29,996.60-17,269.76
Price to Book Ratio-0.00-0.04-0.36-0.36-3.13-5.25
Return on Assets-2,860.46-2,980.89-658.78-599.88-318.61-171.92
Quick Ratio0.030.020.170.180.040.00
Current Ratio0.030.020.170.180.040.00

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-8.76-3.46-8.57-17.94-8.20-1.12
Other Funds (Non Cash)6.30-0.354.522.977.230.52
Funds from Operations-2.46-3.81-4.05-14.97-0.97-0.60
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.181.23-1.084.350.830.24
Income Taxes Payable----0.000.00
Cash from Operating Activities-2.63-2.58-5.13-10.62-0.14-0.36
Capital Expenditures-0.07-0.01-0.010.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.00-1.00-7.41-1E-066.41
Purchase of Investments0.000.00-1.00-0.90-1E-06-0.10
Sale Or Maturity of Investments0.000.000.00-6.510.006.51
Other Uses0.000.000.000.000.000.00
Other Sources0.001.150.00-0.080.000.08
Cash from Investing Activities-0.071.15-1.01-7.49-1E-066.49
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock2.390.476.7410.050.00-6.51
Repurchase of Common Pref Stock0.000.000.006.510.00-6.51
Sale of Common Pref Stock2.390.476.743.540.000.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.66-0.44-1.8311.400.000.00
Change in Long Term Debt1.500.000.0011.000.000.00
Issuance of Long Term Debt1.500.000.0011.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.00-0.510.120.39
Other Financing Activities Uses0.000.000.00---
Cash from Financing Activities3.050.034.9120.940.12-6.13
Net Change in Cash0.34-1.40-1.232.83-0.020.00
Free Cash Flow-2.71-2.58-5.14-10.62-0.14-0.36

Revenue breakdown

Surgical & Medical Instruments & Apparatus2024: 100.00K
United States2024: 100.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3018.95%0.1M0.5M3.47M
2026-10-1514.97%0.1M0.5M2.77M
2026-09-3030.89%0.2M0.5M2.70M
2026-09-156.07%0.0M0.5M1.15M
2026-08-3115.24%0.0M0.3M1.09M
2026-08-141.81%0.0M0.6M86.08K
2026-07-3111.30%0.0M0.1M82.39K
2026-07-1510.04%0.0M0.1M41.00K
2026-06-304.95%0.0M0.0M71.27K
2026-06-152.68%0.0M0.0M47.81K
2026-05-296.27%0.0M0.0M48.11K
2026-05-155.84%0.0M0.0M50.16K
2026-04-3015.76%0.0M0.0M50.95K
2026-04-150.89%0.0M0.0M47.61K
2026-03-313.35%0.0M0.0M4.18K
2026-03-134.76%0.0M0.0M6.15K
2026-02-2732.21%0.0M0.0M6.06K
2026-02-136.18%0.0M0.0M3.73K
2026-01-305.67%0.0M0.0M3.48K
2026-01-153.97%0.0M0.0M3.46K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-11-10SEC
2026-11-068-KCurrent report2026-11-05SEC
2026-10-27SCHEDULE 13G/ASEC
2026-10-158-KCurrent report2026-10-15SEC
2026-10-098-KCurrent report2026-10-05SEC
2026-10-058-KCurrent report2026-10-04SEC
2026-09-218-KCurrent report2026-09-18SEC
2026-09-168-KCurrent report2026-09-16SEC
2026-09-158-KCurrent report2026-09-09SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-08-21SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-08-21SEC
2026-09-018-KCurrent report2026-09-01SEC
2026-08-318-KCurrent report2026-08-26SEC
2026-08-28DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-09-18SEC
2026-08-218-KCurrent report2026-08-12SEC
2026-08-208-KCurrent report2026-08-20SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-07-28SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-08-19SCHEDULE 13DSEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-08-1910-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-07-28SEC
2026-08-18PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-08-18SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-07-28SEC
2026-08-14NT 10-Q2026-06-30SEC
2026-08-148-KCurrent report2026-08-13SEC
2026-08-124Statement of changes in beneficial ownership of securities2026-07-28SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-07-28SEC
2026-08-054Statement of changes in beneficial ownership of securities2026-07-28SEC
2026-08-04SCHEDULE 13G/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-0825.30K5153.23K6
2026-0711.65K300
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
HRT FINANCIAL LP179.57%
StoneX Group Inc.17.73%
GEODE CAPITAL MANAGEMENT, LLC17.24%
VANGUARD CAPITAL MANAGEMENT LLC4.14%
Tower Research Capital LLC3.95%
IFP Advisors, Inc3.15%
MORGAN STANLEY1.68%
FMR LLC0.53%
SBI Securities Co., Ltd.0.38%
SkyView Investment Advisors, LLC0.28%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND4.14%
Fidelity Extended Market Index Fund0.03%
Fidelity Series Total Market Index Fund0.00%
Fidelity Nasdaq Composite Index Fund0.00%

OakChart. PFSA. Cached 15 minutes.

Some panels did not load: ratings.